ReviewNature biotechnology2026
Biomolecular profiling for noninvasive health monitoring.
Review in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biomolecular profiling offers a powerful lens into human physiology, yet current diagnostics often rely on invasive sampling and delayed, centralized analysis. Advances in mass spectrometry (MS), particularly untargeted metabolomics and proteomics, have expanded molecular access to noninvasive biofluids such as sweat, saliva, tears and interstitial fluid, revealing dynamic biomarkers linked to both chronic and acute conditions. In parallel, wearable biosensors enable real-time, on-body chemical sensing, but remain limited to a narrow panel of predefined analytes. This Review highlights how MS-based molecular discovery and wearable sensing serve as complementary approaches-MS enabling high-dimensional untargeted profiling and wearables delivering longitudinal real-time data-and also discusses how their bidirectional integration and co-evolution open new possibilities for personalized noninvasive health monitoring. We discuss advances in sampling strategies, sensing modalities and system integration, and outline criteria for identifying biomarkers amenable to sensor translation. By uniting untargeted discovery with real-world deployment, this convergence shifts personalized noninvasive healthcare from episodic diagnostics to continuous, context-aware monitoring.
Indexed as
Identifiers
41820567What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.